Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222455 | 0.84 | — | — | |
| SCHEMBL222244 | 0.83 | — | — | |
| SCHEMBL221564 | 0.83 | ABL1 (0.53) | ABL1 | |
| SCHEMBL14347505 | 0.83 | ABL1 (0.53) | ABL1 | |
| SCHEMBL221705 | 0.83 | — | — | |
| SCHEMBL2739821 | 0.82 | — | — | |
| SCHEMBL222323 | 0.82 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL221093 | 0.82 | ABL1 (0.53) | ABL1 | |
| SCHEMBL220280 | 0.82 | ABL1 (0.51) | ABL1 | |
| SCHEMBL219615 | 0.82 | ABL1 (0.51) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481544-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-07-09 | — | — | US | claimed |
| US-8481586-B2 | Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-07-09 | — | — | US | claimed |
| US-20100311766-A1 | ANTIBACTERIAL COMPOSITIONS | BIOTA EUROPE LTD (GB) | 2010-12-09 | — | — | US | claimed |
| EP-3102203-A2 | ANTIBACTERIAL COMBINATIONS COMPRISING POLYMYXIN | SPERO GYRASE, INC. (US) | 2016-12-14 | — | — | EP | disclosed |
| WO-2015114452-A2 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2015-08-06 | — | — | WO | disclosed |
| US-8481544-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-20120004221-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| WO-2009074810-A1 | ANTIBACTERIAL COMPOSITIONS | PROLYSIS LTD (GB) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004221-A1 | Antibacterial Compositions | CYCS, COX6C, RPS6 | NPC1 2581/4885RAB9A 3590/4885SMN1; SMN2 3141/4885 |
| US-20100311766-A1 | ANTIBACTERIAL COMPOSITIONS | C5, AGK, CYCS | NPC1 3590/4885RAB9A 1924/4885SMN1; SMN2 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.